Windtree Therapeutics Inc represents a commitment to advancing the field of respiratory medicine through innovative solutions. The company strives for excellence, driving breakthroughs in the treatment of respiratory diseases. With a focus on developing therapeutics for neonatal and pediatric patients, Windtree Therapeutics aims to improve the quality of life for these vulnerable populations. By leveraging their expertise and research capabilities, the company aims to revolutionize respiratory care and bring about positive change in the healthcare industry. Windtree Therapeutics remains dedicated to making a lasting impact and improving patient outcomes through their values of innovation, scientific rigor, and patient-centricity.

Windtree Therapeutics Inc is primarily present in the United States.

Some significant milestones achieved by Windtree Therapeutics Inc include the successful completion of a Phase 2 clinical trial for their lead product candidate, AEROSURF®, which showed positive results in treating respiratory distress syndrome in premature infants. Additionally, the company secured funding through multiple grants and partnerships to support further research and development initiatives. Windtree Therapeutics Inc also advanced their pipeline of potential therapies and received approvals for various patents related to their innovative technologies. With their continued dedication to improving patient care and advancing medical solutions, Windtree Therapeutics Inc has positioned itself as a leading player in the biopharmaceutical industry.

Windtree Therapeutics Inc, formerly known as Discovery Laboratories Inc, is a biotechnology company specializing in developing and commercializing products for respiratory diseases and other healthcare issues. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. Windtree focuses on developing novel therapies using its proprietary technology platform, which includes advanced lipids and synthetic lung surfactant formulations. With a strong commitment to improving patient outcomes, Windtree Therapeutics aims to address unmet medical needs in respiratory care. The company's dedication to innovation and expertise in the field have positioned it as a leader in the development of respiratory therapies.

The main competitors of Windtree Therapeutics Inc in the market are companies like AstraZeneca, GlaxoSmithKline, and Novartis.

Windtree Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Windtree Therapeutics Inc is focused on developing and commercializing innovative therapeutics for respiratory diseases and other indications. Windtree Therapeutics Inc is dedicated to addressing unmet needs in patient care by leveraging its proprietary technology platform. With a focus on improving treatments for respiratory conditions, the company aims to advance its product pipeline to provide better outcomes for patients. Windtree Therapeutics Inc's commitment to innovation, strategic partnerships, and research and development drives its business model and enables the company to deliver novel therapeutic solutions in the healthcare industry.

Το Windtree Therapeutics P/E είναι -0,17.

Το KUV της εταιρείας Windtree Therapeutics είναι 0.

Το AlleAktien Qualitätsscore για το Windtree Therapeutics είναι 2/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Windtree Therapeutics.

Το αναμενόμενη Windtree Therapeutics κέρδος είναι -71,39 Εκ. USD.

Windtree Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for respiratory diseases and lung disorders. The company utilizes an innovative technology platform called Aerosolized KL4 Surfactant to develop aerosolized medications that can directly target and treat affected areas in the lungs.

Η Windtree Therapeutics καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Windtree Therapeutics αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Windtree Therapeutics είναι US97382D3035.

Το WKN της Windtree Therapeutics είναι A2P3ZQ.

Ο τίκερ της Windtree Therapeutics είναι WINT.

Κατά τους τελευταίους 12 μήνες η Windtree Therapeutics κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Windtree Therapeutics προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Windtree Therapeutics ανέρχεται σήμερα στο .

Windtree Therapeutics πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Windtree Therapeutics πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Windtree Therapeutics ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Windtree Therapeutics από την 16/9/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 16/9/2024.

Η τελευταία μερίσματος έγινε στις 16/9/2024.

Το έτος 2023, η Windtree Therapeutics διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Windtree Therapeutics καταβάλλονται σε USD.